Sun Pharma plans to increase field force in India by 10 percent in current fiscal

Replying to a query, Ganorkar termed the intended increase in the field force as "more like an organic growth".;

Published On 2022-06-06 07:00 GMT | Update On 2022-06-06 06:54 GMT

New Delhi: Drug major Sun Pharma plans to increase its field force in the domestic market by 10 per cent in the current fiscal in order to drive twin objectives of brand focus and geographical expansion, according to a senior company official. The Mumbai-based drug major, which is the fourth largest specialty generic drug maker in the world, currently employs around 11,000 Medical Representatives (MRs) and related staff in the country.

"The field force expansion done in FY21 has met with good success and considering the current market conditions, we will be undertaking a further expansion of about 10 per cent for our field force in FY23, driven by the twin objectives of brand focus and geographical expansion," Sun Pharmaceutical Industries CEO (India Business) Kirti Ganorkar said in an analyst call.

The company's India formulations sales for the full year FY22 stood at Rs 12,759 crore recording a strong 23 per cent growth over 2020-21 fiscal.

For the fourth quarter ended March 31, 2022, formulation revenues in India stood at Rs 3,096 crore, about 16 per cent higher over the January-March quarter of FY21.

Replying to a query, Ganorkar termed the intended increase in the field force as "more like an organic growth".

"We are expanding to geographies where we had a limited presence or no presence. So, it's nothing to say that we are looking at competition and then expanding. So, wherever we are seeing growth opportunities in the territories where we are expanding," he noted.

Besides, the company has a large product portfolio which it needs to "declutter", Ganorkar stated.

"That's why we are expanding in terms of the number of MRs as well as in terms of the number of business units, which are promoting products to the doctors. So, it's more of our strategy to grow in the future," he stated.

Ganorkar said the company has witnessed growth across most of the therapies where it has a presence.

"The growth was driven by a combination of factors like normalised market conditions and improved patient flow to doctor clinics, which led to higher growth in the chronic and semi-chronic segments. New products also contributed to the growth and we are seeing good momentum in products launched in the last 24 months," he noted.

In the fourth quarter the company introduced 11 new products in the Indian market.

Supported by more than 40 manufacturing facilities, Sun Pharma caters to more than 100 countries across the globe.

In FY22, the company's topline has crossed the USD 5 billion milestone while the adjusted net profit has gone past the USD 1 billion mark.

Read also: Sun Pharma expects high single-digit top-line growth in FY23

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sun Pharma plans to increase field force in India by 10 percent in current fiscal

Replying to a query, Ganorkar termed the intended increase in the field force as "more like an organic growth".;

Similar News

Lupin partners with Sandoz to market, commercialize Ranibizumab biosimilar across multiple regions

Intas Pharma, Accord signs agreement to buy Prothya Biosolutions

Gland Pharma secures USFDA okay for Norepinephrine Bitartrate in 5% Dextrose Injection Bags

UCPMP 2024: Govt Details Stricter Rules to Curb Gifts, Incentives from Pharma to Doctors

AIOCD Opposes Karnataka's Third-Party Pharmacy Inspection Plan, Warns of Legal, Data Risks

Sun Pharma's Phase IV Study on Dual Release Pantoprazole for GERD Gets CDSCO Panel Acceptance

Draft Rules Set to Regulate Online Sale of Addictive Painkillers, Psychotropic Drugs: Govt

GSK Gepotidacin accepted for priority review by USFDA for oral treatment of uncomplicated urogenital gonorrhoea